Sunitinib, which inhibits many receptors related to STAT3 including the CSF-1 receptor, has been shown to decrease myeloid-derived suppressor cell (MDSC) levels in RCC patients in clinical trial, though it is difficult to determine which specific receptor may be responsible for this effect (48). This evidence concerns the gene STAT3 and renal cell carcinoma.